
CRL AI Price Prediction
Track CRL's AI-powered predictions, market trends, and investment insights.
You don't hold CRL in your mock portfolio yet.
Track CRL's AI-powered predictions, market trends, and investment insights.
You don't hold CRL in your mock portfolio yet.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get StartedThe negative EPS of -2.92 and corresponding negative PE ratio of -63.49 indicate that Charles River Laboratories is currently unprofitable on a GAAP basis, which is a clear negative for equity holders. While the company historically has had a solid position in the contract research and preclinical services market, the current loss-making profile suggests margin pressure, elevated costs, or one‑off charges impacting net income. Until there is clearer evidence of a return to consistent profitability and margin expansion, the financial picture leans negative for the stock.
The stock’s recent 9.3% gain over the last month and price of $185.39 above its 200‑day moving average of $176.03 signal a short‑term positive trend and some technical strength. Trading above the 200‑day moving average often indicates an intermediate‑term uptrend, but the move is not yet extreme enough, by itself, to offset the underlying earnings weakness. In the absence of RSI data, the technical picture is modestly constructive but not decisively bullish.
Alternative data for Charles River Laboratories is mixed to negative, with the most concerning signal being a 95.7% month‑over‑month drop in job openings, which may indicate hiring freezes, cost cutting, or slower anticipated growth. Web traffic of roughly 231k monthly visitors is meaningful for a B2B‑oriented business, but no strong growth signal is provided, and social media metrics show only marginal changes, with LinkedIn as the only notably growing channel. Overall, alternative data does not currently point to strong demand acceleration or aggressive expansion.
Charles River Laboratories presents a mixed picture: technically, the stock is in a short‑term uptrend and trading above its 200‑day moving average, but fundamentals are pressured by negative earnings and a lack of clear profitability. Alternative data, especially the steep drop in job postings, suggests a more cautious or defensive stance by management, which tempers the positive signal from recent price momentum. Taken together, these factors support a neutral view, with upside dependent on evidence of improving margins and a return to sustainable profitability.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Charles River Laboratories (CRL) is currently trading at $187.51 on the NYSE, reflecting a modest single-day decline of 0.3% with a market capitalization of approximately $9.0 billion. Daily volume stands at 401,698 shares, suggesting measured but not negligible investor activity. As a leading non-clinical contract research organization, CRL operates across drug discovery, safety assessment, and manufacturing solutions — three segments that position it at the core of pharmaceutical development pipelines. Despite its structural importance to the biopharma sector, the stock's current technical and sentiment profile warrants careful scrutiny from investors evaluating entry points in 2026.
TrendEdge's AI model assigns CRL a score of 4 out of 10, indicating a below-average outlook based on aggregated signals across price momentum, sentiment, and alternative data. The score reflects limited positive catalysts at present: social sentiment data is sparse, with only a single Reddit mention recorded over the past seven days and no measurable directional sentiment. Web traffic and app download trends are also unavailable, reducing the breadth of alternative data inputs. While CRL's fundamental business remains defensively positioned within contract research, the AI score suggests the market is not currently pricing in near-term upside momentum.
Looking ahead, investors should monitor Charles River Laboratories' order book trends across its DSA and RMS segments, as biopharma R&D budget cycles directly influence contract research demand. Regulatory scrutiny around animal research models and potential client consolidation remain structural risks. With 293 active job postings, the company is maintaining operational investment, which could signal stability or expanding capacity. Any shift in biopharma outsourcing activity or guidance revisions during upcoming earnings would be key catalysts to reassess the current cautious AI-driven outlook.
Unlock comprehensive alternative data signals to make better investment decisions
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Web Traffic
209,034
Twitter Followers
8,959
Instagram Followers
5,673
YouTube Subscribers
4,530
LinkedIn Followers
247,323
Job Postings
291
LinkedIn Employees
14,659
News Mentions
0
Key Metrics